Inhibitor Therapeutics Inc (INTI) - Financial and Strategic SWOT Analysis Review
![](/report_cover/1896/inhibitor-therapeutics-inc-inti-financial-n-strategic-swot-analysis-review_en.gif)
Inhibitor Therapeutics Inc (INTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Inhibitor Therapeutics Inc (Inhibitor) formerly known as Hedgepath Pharmaceuticals Inc, a subsidiary of Mayne Pharma Group Ltd, is a clinical stage biopharmaceutical company that discovers, develops and commercializes novel therapeutics for the treatment of prostrate, and lung cancers. The company is investigating an oral formulation of Itraconazole in phase 2b clinical trials for the treatment of basal cell carcinoma in patients with basal cell carcinoma nevus syndrome. It employs super bioavailability technology (SUBA), a novel drug delivery technology that improves the bioavailability of orally administered drugs which have limited solubility. The company holds an exclusive licensee for Mayne Pharma Group’s SUBA-Itraconazole. Inhibitor is headquartered in Tampa, Florida, the US.
Inhibitor Therapeutics Inc Key Recent Developments
May 03,2020: Inhibitor Therapeutics receives loan under Paycheck Protection Program
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Inhibitor Therapeutics Inc (Inhibitor) formerly known as Hedgepath Pharmaceuticals Inc, a subsidiary of Mayne Pharma Group Ltd, is a clinical stage biopharmaceutical company that discovers, develops and commercializes novel therapeutics for the treatment of prostrate, and lung cancers. The company is investigating an oral formulation of Itraconazole in phase 2b clinical trials for the treatment of basal cell carcinoma in patients with basal cell carcinoma nevus syndrome. It employs super bioavailability technology (SUBA), a novel drug delivery technology that improves the bioavailability of orally administered drugs which have limited solubility. The company holds an exclusive licensee for Mayne Pharma Group’s SUBA-Itraconazole. Inhibitor is headquartered in Tampa, Florida, the US.
Inhibitor Therapeutics Inc Key Recent Developments
May 03,2020: Inhibitor Therapeutics receives loan under Paycheck Protection Program
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Inhibitor Therapeutics Inc - Key Facts
Inhibitor Therapeutics Inc - Key Employees
Inhibitor Therapeutics Inc - Key Employee Biographies
Inhibitor Therapeutics Inc - Major Products and Services
Inhibitor Therapeutics Inc - History
Inhibitor Therapeutics Inc - Company Statement
Inhibitor Therapeutics Inc - Locations And Subsidiaries
Head Office
SECTION 2 – COMPANY ANALYSIS
Company Overview
Inhibitor Therapeutics Inc - Business Description
R&D Overview
Inhibitor Therapeutics Inc - Corporate Strategy
Inhibitor Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Inhibitor Therapeutics Inc - Strengths
Inhibitor Therapeutics Inc - Weaknesses
Inhibitor Therapeutics Inc - Opportunities
Inhibitor Therapeutics Inc - Threats
Inhibitor Therapeutics Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Inhibitor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Inhibitor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Inhibitor Therapeutics Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
May 03, 2020: Inhibitor Therapeutics receives loan under Paycheck Protection Program
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Inhibitor Therapeutics Inc - Key Facts
Inhibitor Therapeutics Inc - Key Employees
Inhibitor Therapeutics Inc - Key Employee Biographies
Inhibitor Therapeutics Inc - Major Products and Services
Inhibitor Therapeutics Inc - History
Inhibitor Therapeutics Inc - Company Statement
Inhibitor Therapeutics Inc - Locations And Subsidiaries
Head Office
SECTION 2 – COMPANY ANALYSIS
Company Overview
Inhibitor Therapeutics Inc - Business Description
R&D Overview
Inhibitor Therapeutics Inc - Corporate Strategy
Inhibitor Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Inhibitor Therapeutics Inc - Strengths
Inhibitor Therapeutics Inc - Weaknesses
Inhibitor Therapeutics Inc - Opportunities
Inhibitor Therapeutics Inc - Threats
Inhibitor Therapeutics Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Inhibitor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Inhibitor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Inhibitor Therapeutics Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
May 03, 2020: Inhibitor Therapeutics receives loan under Paycheck Protection Program
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Inhibitor Therapeutics Inc, Key Facts
Inhibitor Therapeutics Inc, Key Employees
Inhibitor Therapeutics Inc, Key Employee Biographies
Inhibitor Therapeutics Inc, Major Products and Services
Inhibitor Therapeutics Inc, History
Inhibitor Therapeutics Inc, Key Competitors
Inhibitor Therapeutics Inc, Ratios based on current share price
Inhibitor Therapeutics Inc, Annual Ratios
Inhibitor Therapeutics Inc, Annual Ratios (Cont...1)
Inhibitor Therapeutics Inc, Interim Ratios
Inhibitor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Inhibitor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Inhibitor Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Inhibitor Therapeutics Inc, Key Facts
Inhibitor Therapeutics Inc, Key Employees
Inhibitor Therapeutics Inc, Key Employee Biographies
Inhibitor Therapeutics Inc, Major Products and Services
Inhibitor Therapeutics Inc, History
Inhibitor Therapeutics Inc, Key Competitors
Inhibitor Therapeutics Inc, Ratios based on current share price
Inhibitor Therapeutics Inc, Annual Ratios
Inhibitor Therapeutics Inc, Annual Ratios (Cont...1)
Inhibitor Therapeutics Inc, Interim Ratios
Inhibitor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Inhibitor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Inhibitor Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Inhibitor Therapeutics Inc, Performance Chart (2016 - 2020)
Inhibitor Therapeutics Inc, Ratio Charts
Inhibitor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Inhibitor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Inhibitor Therapeutics Inc, Performance Chart (2016 - 2020)
Inhibitor Therapeutics Inc, Ratio Charts
Inhibitor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Inhibitor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021